🇺🇸 FDA
Pipeline program

Odronextamab

R5837-ONC-2019

Phase 1 small_molecule active

Quick answer

Odronextamab for B-cell Non-Hodgkins Lymphoma (B-NHL) is a Phase 1 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
B-cell Non-Hodgkins Lymphoma (B-NHL)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials